$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) HOOKIPA Pharma has announced its decision not to proceed with the previously discussed all-share acquisition of Poolbeg Pharma plc. This decision follows the non-binding discussions announced on January 2, 2025, and a subsequent PUSU extension on January 30, 2025. The company reserves the right to revisit this decision under specific circumstances, including:...
$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV 3 minutes ago, 4:00 AM PST Via GlobeNewswire HOOK Share HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program throug...
$HOOKIPA Pharma (HOOK.US)$ Poolbeg Pharma and HOOKIPA Pharma have provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to: 1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer is m...
$HOOKIPA Pharma (HOOK.US)$ Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA Poolbeg Pharma and HOOKIPA Pharmahave provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to: 1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer ...
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve Show More
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
HOOKIPA Pharma Stock Forum
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
HOOKIPA Pharma has announced its decision not to proceed with the previously discussed all-share acquisition of Poolbeg Pharma plc. This decision follows the non-binding discussions announced on January 2, 2025, and a subsequent PUSU extension on January 30, 2025.
The company reserves the right to revisit this decision under specific circumstances, including:...
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
3 minutes ago, 4:00 AM PST
Via GlobeNewswire
HOOK
Share
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV)
Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program throug...
Poolbeg Pharma and HOOKIPA Pharma have provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer is m...
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
Poolbeg Pharma and HOOKIPA Pharmahave provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer ...
No comment yet